Orforglipron vs Retatrutide
A side-by-side research comparison of Orforglipron and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Orforglipron | Retatrutide |
|---|---|---|
| Full name | Orforglipron (Oral Non-Peptide GLP-1 Agonist) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | ~550 Da | 5,200 Da (approximate) |
| Half-life | 25-60 hours | 6 days |
| Bioavailability | Moderate-High (oral) | High (SubQ) |
| Typical dose | 12-45 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous injection |
Orforglipron reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.